Trending Topic

3D Rendered Medical Illustration of The Lungs.
12 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Asrar A Alahmadi, Logan Roof, Claire Verschraegen

Highlights Immunotherapy, especially combinatory immunotherapy, has shown promise with prolonged survival for patients with advanced mesothelioma in the first-line setting (see the sections on ‘Systemic treatment and immunotherapy debut’ and ‘Randomized immunotherapy trials of mesothelioma’). Histology-based therapy is important to consider, with non-epithelioid subtypes responding better to immunotherapy than to chemotherapy (see the section on […]

Geoffrey Ku, ASCO GI 2021: The Addition of Durvalumab to Chemoradiation for Esophageal Adenocarcinoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 21st 2021

We were delighted to talk to Geoffrey Ku (Memorial Sloan Kettering Cancer Center, New York, US) about the addition of durvalumab to induction FOLFOX and PET-directed chemoradiation for esophageal adenocarcinoma (Clinical Trial Identifier: NCT02962063). The abstract ‘Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma’ (ABSTRACT NUMBER: 226) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.

Questions

  1. Why is there a need for multimodal treatment strategies for patients with esophageal adenocarcinoma? (0:16)
  2. What is the rationale for the addition of durvalumab to the treatment regimen of induction FOLFOX and PET-directed chemoradiation in the treatment of esophageal adenocarcinoma? (1:06)
  3. Could you tell us about your recent study and its findings? (2:23)
  4. What will be the impact of these findings on clinical practice and what further studies are planned? (3:37)

Disclosures: Geoffrey Ku reports Research Support from Arog, AstraZeneca, BMS, Daiichi Sankyo, Merck, Oncolys, Pieris and Zymeworks, and Consulting for Apexigen, BMS, IMAB and Pieris.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of ASCO GI 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup